The use of the slow-release agent Montanide ISA-51 to inject an anti-CTLA-4 antibody peritumorally resulted in local anti-tumor CD8+ T cell activation and tumor eradication associated with thousand-fold lower serum levels of antibody compared to the systemic delivery—reducing the adverse events and the risk of auto-immunity (172). This evidence concerns the gene CTLA4 and neoplasm.